CVRx (NASDAQ:CVRX) Downgraded to “Hold” Rating by Lake Street Capital

Lake Street Capital downgraded shares of CVRx (NASDAQ:CVRX) from a buy rating to a hold rating in a research note issued to investors on Friday, Marketbeat reports. The firm currently has $3.50 price objective on the stock.

CVRX has been the topic of several other research reports. Weiss Ratings restated a “sell (e+)” rating on shares of CVRx in a report on Monday. Piper Sandler lowered CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price objective for the company. in a research report on Friday. Canaccord Genuity Group reissued a “buy” rating and issued a $10.00 price objective on shares of CVRx in a research note on Tuesday, April 14th. Finally, Wall Street Zen upgraded CVRx from a “sell” rating to a “hold” rating in a research report on Saturday, June 27th. One equities research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, CVRx has a consensus rating of “Hold” and an average target price of $6.90.

CVRx Stock Down 59.8%

CVRx stock opened at $2.39 on Friday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 8.89 and a current ratio of 10.20. CVRx has a 52-week low of $2.30 and a 52-week high of $11.30. The firm has a 50 day moving average price of $5.19 and a two-hundred day moving average price of $6.49. The firm has a market cap of $63.43 million, a price-to-earnings ratio of -1.21 and a beta of 0.81.

CVRx (NASDAQ:CVRX) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.01). CVRx had a negative net margin of 84.93% and a negative return on equity of 133.84%. The firm had revenue of $15.71 million during the quarter, compared to the consensus estimate of $15.55 million. Equities analysts predict that CVRx will post -1.89 EPS for the current year.

Institutional Investors Weigh In On CVRx

Several hedge funds and other institutional investors have recently bought and sold shares of CVRX. Geode Capital Management LLC boosted its position in shares of CVRx by 6.4% during the 2nd quarter. Geode Capital Management LLC now owns 382,437 shares of the company’s stock worth $2,249,000 after purchasing an additional 23,079 shares in the last quarter. XTX Topco Ltd bought a new stake in CVRx in the 2nd quarter valued at about $155,000. Marshall Wace LLP increased its position in CVRx by 238.1% in the 2nd quarter. Marshall Wace LLP now owns 350,080 shares of the company’s stock valued at $2,058,000 after buying an additional 246,548 shares in the last quarter. Cresset Asset Management LLC raised its stake in CVRx by 3.5% during the 2nd quarter. Cresset Asset Management LLC now owns 53,542 shares of the company’s stock worth $315,000 after buying an additional 1,823 shares during the period. Finally, Bank of America Corp DE boosted its holdings in CVRx by 7.6% in the second quarter. Bank of America Corp DE now owns 89,049 shares of the company’s stock worth $524,000 after acquiring an additional 6,312 shares in the last quarter. 75.27% of the stock is owned by institutional investors.

Key Stories Impacting CVRx

Here are the key news stories impacting CVRx this week:

• Positive Sentiment: CVRx reported second-quarter revenue of $15.71 million, slightly above the $15.55 million analyst consensus. Its per-share loss of $0.53 was also an improvement from a $0.57 loss a year earlier, although it narrowly missed the $0.52 consensus loss. CVRx Reports Second Quarter 2026 Financial and Operating Results
• Positive Sentiment: Despite downgrading the shares to “hold,” Lake Street Capital and Craig Hallum set price targets of $3.50 and $4.00, respectively—above the current trading level—suggesting potential recovery if execution improves. The Fly analyst ratings
• Neutral Sentiment: Johnson Fistel said it is investigating whether CVRx or certain executives violated securities laws in connection with the guidance reduction and sales-execution disclosures. The announcement is an investigation notice, not a finding of wrongdoing, but it adds headline and legal risk. Johnson Fistel investigation notice
• Negative Sentiment: CVRx cut third-quarter revenue guidance to $13.5 million-$14.5 million, well below the $16.9 million consensus, and reduced full-year 2026 revenue guidance to $58 million-$60 million from an implied level near the $65.4 million consensus. Management cited slower sales productivity and Medicare Advantage-related headwinds. CVRx forecasts 2026 revenue
• Negative Sentiment: The quarterly loss slightly exceeded expectations, while CVRx continues to report deeply negative profitability, including a negative net margin and negative return on equity. Analysts responded by downgrading the stock from “buy” to “hold,” reinforcing concerns about near-term growth and execution. CVRx Q2 2026 earnings call transcript

CVRx Company Profile

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.